Premium
Lurasidone‐Induced Tardive Syndrome
Author(s) -
Tripathi Richa,
Reich Stephen G.,
Scorr Laura,
Guardiani Elizabeth,
Factor Stewart A.
Publication year - 2019
Publication title -
movement disorders clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 18
ISSN - 2330-1619
DOI - 10.1002/mdc3.12812
Subject(s) - akathisia , lurasidone , parkinsonism , antipsychotic , tardive dyskinesia , medicine , neuroleptic malignant syndrome , schizophrenia (object oriented programming) , psychiatry , atypical antipsychotic , dopamine receptor , psychology , pediatrics , dopamine , disease
Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor‐blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS. Methods Case series. Results We describe 4 patients who developed tardive dystonia, tardive akathisia, and drug‐induced parkinsonism with the use of the atypical antipsychotic, lurasidone, which was U.S. Food and Drug Administration approved in 2013 for use in bipolar disorder and schizophrenia. Conclusion Movement disorders are reported as a rare side effect of lurasidone, and, as such, prescribers may perceive a false sense of security regarding this potential complication. Our cases indicate that this relatively new atypical antipsychotic may cause irreversible disabling TS as well as parkinsonism. Caution must be taken when prescribing lurasidone.